{"denoms":[{"counts":[{"groupId":"BG000","value":"82"}],"units":"Participants"}],"groups":[{"description":"Adult participants aged 18 years or older, with multiple myeloma received the lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion and fludarabine 30 mg/m\\^2 IV infusion daily, for 3 days \\[Day -7 to Day -5\\]). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants received IV infusion of cilta-cel OOS at a total targeted dose of 0.75\\*10\\^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg (dose range 0.5\\*10\\^6 CAR-positive viable T cells/kg to 1.0\\*10\\^6 CAR-positive viable T cells/kg) based on participant's body weight at apheresis or per exceptional release criteria determined alternative dose.","id":"BG000","title":"Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.58","value":"65.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"47"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"76"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"55"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"82"}]}],"title":"UNITED STATES"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"The all treated analysis set included all participants who received study intervention (cilta-cel out-of-specifications \\[OOS\\])."}